Numerous trials have found that PD-L1-positive tumors had a higher overall response rate to ICB agents in patients with melanoma, NSCLC, Merkel cell carcinoma, renal cell carcinoma, and colorectal cancer than those with PD-L1 negative tumors [18–20]. This evidence concerns the gene CD274 and melanoma.